Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

Oncotarget

Volumn 6, Issue 7, 2015, Pages 5147-5163

  Li, Feng ^a   Shanmugam, Muthu K ^a   Siveen, Kodappully Sivaraman ^a   Wang, Fan ^a,b   Ong, Tina H ^c   Loo, Ser Yue ^a,b,d   Swamy, Mahadeva M M ^e   Mandal, Somnath ^e   Kumar, Alan Prem ^a,b,f,g   Goh, Boon Cher ^a,b,h   Kundu, Tapas ^e   Ahn, Kwang Seok ⁱ   Wang, Ling Zhi ^a,b   Hui, Kam Man ^c   Sethi, Gautam ^a,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^f CURTIN UNIVERSITY   (Australia)

^g UNIVERSITY OF NORTH TEXAS   (United States)

^h NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁱ Kyung Hee University   (South Korea)

Author keywords

Chemoresistance; Garcinol; HNSCC; NF B; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOPHENONE DERIVATIVE; CISPLATIN; CYCLIN D1; GARCINOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROTEIN BCL 2; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER; MESSENGER RNA; PLANT EXTRACT; TERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CAPILLARY DENSITY; CARCINOMA CELL; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENE PRODUCT; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; SYSTEMIC THERAPY; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; \GARCINOL; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; PLANT EXTRACTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TERPENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925004160     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2881     Document Type: Article

References (67)

1. Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Current opinion in pharmacology. 2009; 9:389-395.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008; 371:1695-1709.
3. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer cell. 2004; 5:311-316.
4. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22:1743-1752.
5. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L, Cancer Care Ontario Practice Guideline Initiative H, and Neck Cancer Disease Site G. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head & neck. 2001; 23:579-589.
6. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer treatment reviews. 2007; 33:9-23.
7. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. International journal of radiation oncology, biology, physics. 2000; 47:1-12.
8. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nature clinical practice Oncology. 2007; 4:156-171.
9. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Molecular carcinogenesis. 1999; 26:119-129.
10. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, Van Waes C. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7:435-442.
11. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. International journal of cancer Journal international du cancer. 2006; 119:2840-2850.
12. Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer. 2001; 92:3037-3044.
13. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr., Van Waes C. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer research. 2004; 64:6511-6523.
14. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head & neck. 2007; 29:959-971.
15. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral oncology. 2009; 45:324-334.
16. Dong G, Loukinova E, Chen Z, Gangi L, Chanturita TI, Liu ET, Van Waes C. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer research. 2001; 61:4797-4808.
17. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer research. 2006; 66:8210-8218.
18. Zhang PL, Pellitteri PK, Law A, Gilroy PA, Wood GC, Kennedy TL, Blasick TM, Lun M, Schuerch C, 3rd and Brown RE. Overexpression of phosphorylated nuclear factor- kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2005; 18:924-932.
19. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC medical genomics. 2008; 1:59.
20. Eichholtz-Wirth H, Sagan D. IkappaB/NF-kappaB mediated cisplatin resistance in HeLa cells after low-dose gamma-irradiation is associated with altered SODD expression. Apoptosis: an international journal on programmed cell death. 2000; 5:255-263.
21. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochimica et biophysica acta. 2010; 1805:167-180.
22. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochemical pharmacology. 2002; 63:1423-1430.
23. Wu ZH, Wong ET, Shi YL, Niu JX, Chen ZJ, Miyamoto S, Tergaonkar V. ATM- and NEMO-Dependent ELKS Ubiquitination Coordinates TAK1-Mediated IKK Activation in Response to Genotoxic Stress. Mol Cell. 2010; 40:75-86.
24. Teo HL, Ghosh S, Luesch H, Ghosh A, Wong ET, Malik N, Orth A, de Jesus P, Perry AS, Oliver JD, Tran NL, Speiser LJ, Wong M, Saez E, Schultz P, Chanda SK, et al. Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappa B-dependent gene expression. Nature cell biology. 2010; 12:758-U726.
25. Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P, Yuen AP. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer research. 2007; 67:8800-8809.
26. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical reviews in oncology/hematology. 2007; 63:12-31.
27. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 2007; 130:769-774.
28. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chemical reviews. 2009; 109:3012-3043.
29. Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. Padhye S, Ahmad A, Oswal N, Sarkar FH. J Hematol Oncol. 2009 Sep 2;2:38. doi: 10.1186/1756-8722-2-38.
30. Yamaguchi F, Ariga T, Yoshimura Y, Nakazawa H. Antioxidative and anti-glycation activity of garcinol from Garcinia indica fruit rind. Journal of agricultural and food chemistry. 2000; 48:180-185.
31. Chatterjee A, Yasmin T, Bagchi D, Stohs SJ. The bactericidal effects of Lactobacillus acidophilus, garcinol and Protykin compared to clarithromycin, on Helicobacter pylori. Molecular and cellular biochemistry. 2003; 243:29-35.
32. Liao CH, Sang S, Liang YC, Ho CT, Lin JK. Suppression of inducible nitric oxide synthase and cyclooxygenase-2 in downregulating nuclear factor-kappa B pathway by Garcinol. Molecular carcinogenesis. 2004; 41:140-149.
33. Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. Journal of agricultural and food chemistry. 2001; 49:1464-1474.
34. Liao CH, Sang S, Ho CT, Lin JK. Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells. Journal of cellular biochemistry. 2005; 96:155-169.
35. Ahmad A, Wang Z, Ali R, Maitah MY, Kong D, Banerjee S, Padhye S, Sarkar FH. Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. Journal of cellular biochemistry. 2010; 109:1134-1141.
36. Yoshida K, Tanaka T, Hirose Y, Yamaguchi F, Kohno H, Toida M, Hara A, Sugie S, Shibata T, Mori H. Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Cancer letters. 2005; 221:29-39.
37. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. The Journal of biological chemistry. 2004; 279:33716-33726.
38. Ahmad A, Sarkar SH, Aboukameel A, Ali S, Biersack B, Seibt S, Li Y, Bao B, Kong D, Banerjee S, Schobert R, Padhye SB, Sarkar FH. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis. 2012; 33:2450-2456.
39. Li F, Shanmugam MK, Chen L, Chatterjee S, Basha J, Kumar AP, Kundu TK, Sethi G. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer prevention research. 2013; 6:843-854.
40. Prasad S, Ravindran J, Sung B, Pandey MK, Aggarwal BB. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Molecular cancer therapeutics. 2010; 9:856-868.
41. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21:864-870.
42. Sethi G, Tergaonkar V. Potential pharmacological control of the NF-kappaB pathway. Trends in pharmacological sciences. 2009; 30:313-321.
43. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Bioscience reports. 2012; 32:1-15.
44. Dey A, Wong E, Kua N, Teo HL, Tergaonkar V, Lane D. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell cycle. 2008; 7:3759-3767.
45. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK, Zhou J, Chng WJ, Li S, Liu E, Tergaonkar V. Telomerase directly regulates NF-kappaB-dependent transcription. Nature cell biology. 2012; 14:1270-1281.
46. Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert opinion on emerging drugs. 2010; 15:355-373.
47. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer science. 2008; 99:1507-1514.
48. Parasramka MA, Gupta SV. Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells. Nutrition and cancer. 2011; 63:456-465.
49. Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PloS one. 2014; 9:e93208.
50. Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Archives of otolaryngology- head & neck surgery. 2011; 137:499-507.
51. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31:1869-1883.
52. Kim IK, Park SM, Cho HJ, Baek KE, Nam IK, Park SH, Ryu KJ, Ryu J, Choi J, Hong SC, Kim JW, Lee CW, Kang SS, Yoo J. 1-3-3 sigma attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. Oncotarget. 2013; 4:2045-2056.
53. Ferguson PJ, Vincent M, Min WP, Zheng XF, Koropatnick J. Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget. 2014; 5:2778-2791.
54. Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget. 2014; 5:6620-6632.
55. Wang YF, Chang CJ, Chiu JH, Lin CP, Li WY, Chang SY, Chu PY, Tai SK, Chen YJ. NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment. Oncotarget. 2014; 5:7392-7405.
56. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochemical pharmacology. 2002; 63:1709-1716.
57. Almeida LO, Abrahao AC, Rosselli-Murai LK, Giudice FS, Zagni C, Leopoldino AM, Squarize CH, Castilho RM. NFkappaB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS open bio. 2014; 4:96-104.
58. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, Faull KF, Srivatsan ES, Wang MB. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway. Molecular cancer therapeutics. 2010; 9:2665-2675.
59. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews Cancer. 2002; 2:161-174.
60. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion & metastasis. 1994; 14:109-122.
61. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. Journal of cellular physiology. 2002; 190:279-286.
62. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer metastasis reviews. 2000; 19:19-27.
63. Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH, Gupta S. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Molecular nutrition & food research. 2013; 57:235-248.
64. Parasramka MA, Gupta SV. Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells. Journal of oncology. 2012; 2012:709739.
65. Du T, Nagai Y, Xiao Y, Greene MI, Zhang H. Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Experimental and molecular pathology. 2013; 95:38-45.
66. Chen X, Zhang X, Lu Y, Shim JY, Sang S, Sun Z, Chen X. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol. Nutrition and cancer. 2012; 64:1211-1218.
67. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, Luk JM, Sethi G. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer prevention research. 2012; 5:631-643.